Terazosin in the chronic treatment of the urinary symptoms associated with benign prostatic hyperplasia
OwnerHarriet N. Glassman, David C. Jordan +2inventors
InventorsHARRIET N. GLASSMAN, DAVID C. JORDAN, HERBERT LEPOR, ROBERT R. LUTHER
Life of this patent
Estimating the term…
Abstract
Once daily administration of between 1 mg and 20 mg of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetraydro-2-furanyl)carbonyl]piperazine (terazosin) or a pharmaceutically acceptable salt thereof provides a safe and effective means for the chronic treatment of the urinary symptoms associated with benign prostatic hyperplasia. Treatment with terazosin resulted in about 43% reduction in symptoms and a 26% increase in peak urine flow rates compared with baseline.
Claims8
A method for the chronic treatment of urinary symptoms associated with benign prostatic hyperplasia comprising administering to a male human patient in need of such treatment a therapeutically-effective amount of 1(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)-carbonyl]piperazine or a pharmaceutically-acceptable salt thereof.
A method for the chronic treatment of urinary symptoms associated with benign prostatic hyperplasia comprising administering to a male human patient in need of such treatment a therapeutically-effective amount of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)-carbonyl]piperazine monohydrochloride dihydrate.
Dependencies are inferred from the claim text.